The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Prophylactic tocilizumab to mitigate CRS in patients with R/R myeloma receiving talquetamab
In this video, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, discusses the potential of using prophylactic tocilizumab to mitigate cytokine release syndrome (CRS) in patients with relapsed/refractory (R/R) myeloma receiving talquetamab. Preliminary results from an ongoing study indicate a significant reduction in CRS compared to historical controls, allowing for outpatient treatment and an improvement in patient care. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The latest directions in treatment are really very exciting and there are two modalities, the CAR-Ts and the bispecifics. And one of the side effects that’s common to both of them is this cytokine release syndrome. And a lot of patients these days are being mandated that they’re admitted to hospital for step-up regimens to allow us to mitigate the side effects...
The latest directions in treatment are really very exciting and there are two modalities, the CAR-Ts and the bispecifics. And one of the side effects that’s common to both of them is this cytokine release syndrome. And a lot of patients these days are being mandated that they’re admitted to hospital for step-up regimens to allow us to mitigate the side effects. So this study particularly looks at the role of using tocilizumab prophylactically in the context of talquetamab to ask if you give tocilizumab up front, does it ablate CRS completely? And so if you could do that, well, then you could manage all of these patients at home. They wouldn’t have to be in hospital and things would be much better for the patients. And I think the exciting take home message from this study, which is half completed and so is subject to change. But compared to historical controls, there was barely any CRS. And so in our own practice in New York, we’ve started to allow people to go home with either good advice or with prophylactic tocilizumab. And I think it’s been successful and is really the way forward for everybody.
Read more...
